[Thymic epithelial populations: recently reunified through a unique stem cell].

Med Sci (Paris)

Université Paris Descartes - site Broussais CS61431, 14, rue Maria Helena Vieira Da Silva, batiment Leriche-porte 14, pièce L-507, 75993 Paris Cedex 14, France.

Published: September 2015

Download full-text PDF

Source
http://dx.doi.org/10.1051/medsci/20153106006DOI Listing

Publication Analysis

Top Keywords

[thymic epithelial
4
epithelial populations
4
populations reunified
4
reunified unique
4
unique stem
4
stem cell]
4
[thymic
1
populations
1
reunified
1
unique
1

Similar Publications

Background: Thymoma is a rare mediastinal neoplasm originating from thymic epithelial cells, often associated with paraneoplastic syndromes. These syndromes can manifest as a range of autoimmune disorders, including myasthenia gravis, pure red cell aplasia, and aplastic anemia. Clinical trials involving the use of immune checkpoint inhibitors (ICIs) in thymoma have been complicated by a high incidence of immune-related adverse effects (irAEs).

View Article and Find Full Text PDF

Background And Objective: Thymic epithelial tumors, including thymomas and thymic carcinomas, represent the most common mediastinal tumors and account for up to 50% of all anterior mediastinal tumors. For early stages of these thymic tumors, complete resection of the entire thymus is the recommended treatment. The transition from open surgery to video-assisted thoracoscopic surgery (VATS) and recently to robotic-assisted thoracic surgery (RATS) has fundamentally altered the treatment of thymic tumors.

View Article and Find Full Text PDF

Current immunotherapy for thymic epithelial tumors: a narrative review.

Mediastinum

October 2024

Department of General Thoracic Surgery, Graduate School of Medicine, Osaka University, Osaka, Japan.

Background And Objective: Thymic epithelial tumors (TETs) are the most common neoplasm of the prevascular mediastinal compartment and are characterized by their rarity and variable clinical presentation. The present study aimed to explore the current management of patients with TET with a special focus on immunotherapy for advanced disease.

Methods: Relevant studies published between 1981 and 2024 were searched in PubMed using search terms "Thymoma", "Thymic cancer", "Myasthenia gravis", "Radiation therapy", "Surgery", and "Immunotherapy".

View Article and Find Full Text PDF

Thymic epithelial tumors (TETs) are rare neoplasms that include thymomas, thymic carcinomas (TCs), and thymic neuroendocrine neoplasms (TNENs). These three tumor categories differ in aggressiveness, the incidence of recurrence after resection, the pattern of recurrence, and survival outcomes. Owing to the tumor's rarity, randomized trials have not been performed in the initial treatment setting.

View Article and Find Full Text PDF

Background: Chronic graft-versus-host disease (cGVHD) manifests with characteristics of autoimmune disease with organs attacked by pathogenic helper T cells. Recent studies have highlighted the role of T cells in cGVHD pathogenesis. Due to limited understanding of underlying mechanisms, preventing cGVHD after allogenic hematopoietic cell transplantation (HCT) has become a major challenge.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!